PHASE I STUDY OF BB 10010 IN PATIENTS WITH RELASPED/REFRACTORY BREAST CANCER

BB 10010 在复发/难治性乳腺癌患者中的 I 期研究

• 批准号: 6117768
• 负责人: Michael Gordon
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117768
• 关键词: antineoplastics; blood cell count; bone marrow; breast neoplasms; chemokine; clinical research; clinical trial phase I; drug adverse effect; drug screening /evaluation; human subject; immunosuppression; neoplasm /cancer chemotherapy

Dose-intensive chemotherapy is associated with myelosuppressive complications including neutropenia and theombocytopenia. Currently availabe hamatopoietic growth factors are able to reduce the former complication, but thrombocytopenia, and cumulative myelosuppression remain significant complications of these treatments.

剂量密集型化疗与骨髓抑制有关 并发症，包括中性粒细胞减少症和综合细胞减少症。 现在 可用的hamatopoietic增长因素能够减少前者 并发症，但血小板减少症和累积骨髓抑制仍然存在 这些治疗的重大并发症。